100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C trial [abstract] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C trial [abstract]

Naggie S, Fierer DS, Hughes M, et al. 100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C trial [abstract]. Hepatology. 2017;66(Suppl.):196.

Publication Type:

Journal Article

Authors:

Naggie, S; Fierer, DS; Hughes, M; et, al

Source:

Hepatology, Volume 66, Issue Suppl., p.196 (2017)

Cited On:

Management of Acute HCV Infection

Export Citation:

RIS Format

Top